170 related articles for article (PubMed ID: 17692025)
1. Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.
Lindsley CW; Barnett SF; Yaroschak M; Bilodeau MT; Layton ME
Curr Top Med Chem; 2007; 7(14):1349-63. PubMed ID: 17692025
[TBL] [Abstract][Full Text] [Related]
2. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update.
Lindsley CW
Curr Top Med Chem; 2010; 10(4):458-77. PubMed ID: 20180757
[TBL] [Abstract][Full Text] [Related]
3. The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation.
Barnett SF; Bilodeau MT; Lindsley CW
Curr Top Med Chem; 2005; 5(2):109-25. PubMed ID: 15853641
[TBL] [Abstract][Full Text] [Related]
4. Developments in selective small molecule ATP-targeting the serine/threonine kinase Akt/PKB.
Wang P; Zhang L; Hao Q; Zhao G
Mini Rev Med Chem; 2011 Nov; 11(13):1093-107. PubMed ID: 22353219
[TBL] [Abstract][Full Text] [Related]
5. The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors.
Lindsley CW; Barnett SF; Layton ME; Bilodeau MT
Curr Cancer Drug Targets; 2008 Feb; 8(1):7-18. PubMed ID: 18288939
[TBL] [Abstract][Full Text] [Related]
6. Akt Pathway Inhibitors.
Uko NE; Güner OF; Matesic DF; Bowen JP
Curr Top Med Chem; 2020; 20(10):883-900. PubMed ID: 32091335
[TBL] [Abstract][Full Text] [Related]
7. Covalent-Allosteric Kinase Inhibitors.
Weisner J; Gontla R; van der Westhuizen L; Oeck S; Ketzer J; Janning P; Richters A; Mühlenberg T; Fang Z; Taher A; Jendrossek V; Pelly SC; Bauer S; van Otterlo WA; Rauh D
Angew Chem Int Ed Engl; 2015 Aug; 54(35):10313-6. PubMed ID: 26110718
[TBL] [Abstract][Full Text] [Related]
8. Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises.
Pervanidis KA; D'Angelo GD; Weisner J; Brandherm S; Rauh D
J Med Chem; 2024 Apr; 67(8):6052-6063. PubMed ID: 38592948
[TBL] [Abstract][Full Text] [Related]
9. Development for anticancer therapy: small-molecule inhibitors targeting protein kinase B.
Chen SF; Chen JZ
Mini Rev Med Chem; 2013 Jul; 13(9):1272-94. PubMed ID: 22512570
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.
Mattmann ME; Stoops SL; Lindsley CW
Expert Opin Ther Pat; 2011 Sep; 21(9):1309-38. PubMed ID: 21635152
[TBL] [Abstract][Full Text] [Related]
11. Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination.
Jo H; Lo PK; Li Y; Loison F; Green S; Wang J; Silberstein LE; Ye K; Chen H; Luo HR
Proc Natl Acad Sci U S A; 2011 Apr; 108(16):6486-91. PubMed ID: 21464312
[TBL] [Abstract][Full Text] [Related]
12. Targeted small-molecule inhibitors of protein kinase B as anticancer agents.
Collins I
Anticancer Agents Med Chem; 2009 Jan; 9(1):32-50. PubMed ID: 19149480
[TBL] [Abstract][Full Text] [Related]
13. Novel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain.
Meuillet EJ
Curr Med Chem; 2011; 18(18):2727-42. PubMed ID: 21649580
[TBL] [Abstract][Full Text] [Related]
14. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.
Politz O; Siegel F; Bärfacker L; Bömer U; Hägebarth A; Scott WJ; Michels M; Ince S; Neuhaus R; Meyer K; Fernández-Montalván AE; Liu N; von Nussbaum F; Mumberg D; Ziegelbauer K
Int J Cancer; 2017 Jan; 140(2):449-459. PubMed ID: 27699769
[TBL] [Abstract][Full Text] [Related]
15. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors.
Blake JF; Xu R; Bencsik JR; Xiao D; Kallan NC; Schlachter S; Mitchell IS; Spencer KL; Banka AL; Wallace EM; Gloor SL; Martinson M; Woessner RD; Vigers GP; Brandhuber BJ; Liang J; Safina BS; Li J; Zhang B; Chabot C; Do S; Lee L; Oeh J; Sampath D; Lee BB; Lin K; Liederer BM; Skelton NJ
J Med Chem; 2012 Sep; 55(18):8110-27. PubMed ID: 22934575
[TBL] [Abstract][Full Text] [Related]
16. Discovery of inter-domain stabilizers-a novel assay system for allosteric akt inhibitors.
Fang Z; Simard JR; Plenker D; Nguyen HD; Phan T; Wolle P; Baumeister S; Rauh D
ACS Chem Biol; 2015 Jan; 10(1):279-88. PubMed ID: 24959717
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoinformatic Approaches to Design Novel Inhibitors of Protein Kinase B Pathways in Cancer.
Akhtar N; Jabeen I
Curr Cancer Drug Targets; 2018; 18(9):830-846. PubMed ID: 28669343
[TBL] [Abstract][Full Text] [Related]
18. ATP-competitive and allosteric inhibitors induce differential conformational changes at the autoinhibitory interface of Akt1.
Shaw AL; Parson MAH; Truebestein L; Jenkins ML; Leonard TA; Burke JE
Structure; 2023 Mar; 31(3):343-354.e3. PubMed ID: 36758543
[TBL] [Abstract][Full Text] [Related]
19. FCX-146, a potent allosteric inhibitor of Akt kinase in cancer cells: Lead optimization of the second-generation arylidene indanone scaffold.
Balasubramaniam M; Lakkaniga NR; Dera AA; Fayi MA; Abohashrh M; Ahmad I; Chandramoorthy HC; Nalini G; Rajagopalan P
Biotechnol Appl Biochem; 2021 Feb; 68(1):82-91. PubMed ID: 32067263
[TBL] [Abstract][Full Text] [Related]
20. PDK1 and PKB/Akt: ideal targets for development of new strategies to structure-based drug design.
Harris TK
IUBMB Life; 2003 Mar; 55(3):117-26. PubMed ID: 12822887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
